Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00149799 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00149799: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00149799 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00149799, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.
Interventions
- DRUG Placebo
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00149799
The ClinicalTrials.gov registry entry for NCT00149799 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00149799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00149799 about?
NCT00149799 is a clinical study titled "Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder". This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.
What is the current status of trial NCT00149799?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2005-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00149799?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00149799?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.